Cancer Drug Shortages Are Disrupting Treatment: What Patients Should Know
Imagine showing up for chemotherapy and learning that one of the drugs in your treatment plan is in short supply.
For cancer patients, that is more than an inconvenience. Cancer treatment is often carefully planned around specific drugs, doses, and schedules. A shortage can force hospitals and oncology teams to search for alternatives, conserve available supplies, work with pharmacies, and sometimes seek new approval from insurance companies.
A new survey from the National Comprehensive Cancer Network (NCCN) shows how widespread the problem has become.
In the survey, 100% of responding NCCN cancer centers reported a shortage of at least one anticancer medication. More than 20% reported shortages of five or more cancer drugs at the same time.
Among the responding centers:
94% reported an ifosfamide shortage
71% reported a carboplatin shortage
16% reported a cisplatin shortage
More than half reported shortages of BCG, an immunotherapy used for bladder cancer.
These are not experimental cancer drugs.
Many are older medications that have been used for decades and remain important parts of standard cancer treatment.
Key Takeaways
Cancer drug shortages do not automatically mean a patient will miss treatment. Cancer centers often use inventory management, alternative drugs, different treatment schedules, and other strategies to keep care on track.
However, shortages can make cancer treatment more complicated.
The new NCCN survey found that 61% of responding centers needed pharmacy- and physician-led strategies to keep patients on recommended doses and schedules. When treatment plans had to change, 90% said the new plan required repeat insurance prior authorization, creating another possible source of delay.
For patients, the most important advice is simple:
If you are receiving chemotherapy, ask your oncology team whether any medications in your treatment plan are affected by current shortages and what the backup plan would be if supply becomes limited.
How Serious Are Cancer Drug Shortages in 2026?
The latest NCCN survey was conducted among pharmacy directors and other leaders at NCCN Member Institutions in late August 2026.
Every responding institution reported at least one current anticancer drug shortage.
The problem is also not new.
NCCN began formally tracking chemotherapy shortages in 2023, when the United States faced major shortages of carboplatin and cisplatin.
Three years later, the situation has not improved much.
When NCCN asked pharmacy directors whether national or state policies had improved cancer drug shortages since 2023, only 4% said the situation had improved. Ninety-six percent said it had stayed about the same.
That is concerning because some of the affected medications are basic building blocks of cancer treatment.
Which Cancer Drugs Are in Short Supply?
Ifosfamide
The most widely reported shortage in the NCCN survey involved ifosfamide.
Ninety-four percent of responding centers reported supply problems with the drug.
Ifosfamide is an older chemotherapy drug that damages cancer-cell DNA and prevents the cells from dividing. It is FDA approved as part of combination chemotherapy for certain testicular cancers and is also used in treatment regimens for other cancers.
Ifosfamide can also be part of multi-drug chemotherapy combinations. For example, the ICE regimen combines ifosfamide, carboplatin, and etoposide and can be used for certain lymphomas.
That means one shortage can potentially affect more than one type of cancer treatment.
Carboplatin
Carboplatin was in short supply at 71% of responding NCCN centers.
Carboplatin is a platinum-based chemotherapy drug that damages DNA inside cancer cells. It is widely used across oncology, often as part of combination therapy.
Carboplatin shortages are particularly notable because shortages of carboplatin and cisplatin were among the reasons NCCN began tracking the cancer drug shortage problem in 2023.
Cisplatin
Another platinum chemotherapy, cisplatin, was reported in shortage at 16% of responding centers.
Cisplatin is used in treatment regimens for several cancers and works by forming DNA cross-links that interfere with cancer-cell growth.
Sometimes carboplatin and cisplatin can serve similar roles, but they are not automatically interchangeable.
Which drug is appropriate depends on the type of cancer, treatment goal, scientific evidence, the patient's health, and the specific treatment regimen.
Patients should never assume one chemotherapy drug can simply be swapped for another.
Why Are Cancer Drugs Running Short?
It seems strange that the United States can develop highly advanced cancer treatments while struggling to maintain supplies of drugs that have existed for decades.
But older drugs can actually be especially vulnerable.
The FDA says manufacturing quality problems are the most common cause of drug shortages. Other causes include:
Production delays
Shortages of raw materials or components
Shipping problems
Unexpected increases in demand
Manufacturers discontinuing a drug
Limited manufacturing capacity.
There is also an economic issue.
Many older cancer drugs are inexpensive generics.
That sounds like a good thing for patients, but very low prices can make the drugs less attractive for manufacturers to produce.
The FDA's analysis of drug shortages identified a lack of economic incentives to manufacture some less-profitable drugs as one of the underlying causes of shortages.
FDA also notes that generic and off-patent drugs are especially vulnerable to shortages and account for more than 80% of drug shortages overall.
Think of it like having only a few factories manufacturing a critical replacement part.
As long as every factory is operating normally, there may be enough supply.
But if one factory shuts down because of a quality problem, equipment failure, raw-material problem, or business decision, the remaining factories may not be able to suddenly double production.
Cancer centers can then find themselves competing for a limited supply of a medicine patients need now.
Does a Drug Shortage Mean My Chemotherapy Will Be Delayed?
Not necessarily.
This is one of the most important things for patients to understand.
A hospital reporting a shortage does not mean it has completely run out of the medication.
Hospitals may have limited inventory and need to carefully manage that supply.
The FDA also defines a national drug shortage differently from a temporary local supply problem. A drug is considered in shortage at the national level when current or projected demand exceeds available supply across the country. A hospital or pharmacy can sometimes experience a local supply issue even when the FDA does not classify the drug as being in national shortage.
Cancer centers use several strategies to keep treatment moving.
The NCCN survey found that 61% of responding institutions required coordinated pharmacy and physician strategies to maintain recommended treatment schedules. Those strategies included reducing medication waste and considering other guideline-supported regimens when appropriate.
What Do Doctors Do When a Chemotherapy Drug Is Unavailable?
There is no single answer.
The response depends on the cancer, the drug, how limited the supply is, and whether scientifically supported alternatives exist.
ASCO has published clinical guidance for cancer drug shortages. Among its recommendations are:
Use an alternative drug or treatment sequence with comparable effectiveness and safety when one exists.
Adjust treatment intervals or doses when doing so is clinically acceptable.
Reduce medication waste through dose rounding, vial management, and other pharmacy strategies.
Use evidence-based alternative treatment regimens when adequate supplies are unavailable.
Create multidisciplinary teams to monitor shortages and make allocation decisions fairly.
That does not mean every chemotherapy drug has an easy substitute.
Sometimes there may be several reasonable treatments.
Other times a specific medication may be considered the best available option.
That is why shortage decisions involve oncologists, pharmacists, nurses, hospital administrators, and sometimes ethics or drug-allocation committees.
Cancer Drug Shortages Can Create a Second Problem: Insurance Delays
Finding an alternative treatment may only be the first hurdle.
The NCCN survey found that when cancer centers changed treatment plans because of a shortage, 90% reported needing repeat prior authorization from the patient's insurance company.
Prior authorization means the insurer must approve the new treatment before it will agree to pay for it.
Imagine that Drug A is part of an approved chemotherapy plan.
Drug A suddenly becomes unavailable.
The oncologist decides Drug B is an appropriate evidence-based alternative.
The medical team may then have to go back to the insurer and explain why the treatment changed.
That creates more paperwork for an oncology team already dealing with the shortage itself and can introduce another opportunity for treatment disruption.
This illustrates an important point:
A cancer drug shortage is not only a medication supply problem. It can become a scheduling, insurance, pharmacy, and patient-care problem at the same time.
Why Treatment Disruption Matters
Cancer treatment schedules are designed for a reason.
Depending on the cancer, patients may receive therapy every week, every two weeks, every three weeks, or according to another carefully designed schedule.
Some delays are medically necessary. For example, treatment may be postponed because blood counts have not recovered or because a patient needs time to recover from toxicity.
A drug shortage creates a different problem.
It can introduce a treatment change that has nothing to do with the patient's cancer or health.
Cancer centers work hard to prevent shortages from causing unnecessary interruptions, but the NCCN findings show the amount of effort required behind the scenes.
Pharmacists may have to manage limited inventory.
Doctors may have to identify alternatives.
Insurance teams may have to obtain new approval.
Infusion schedules may have to be adjusted.
And patients may have to deal with additional uncertainty during an already difficult time.
What Should Cancer Patients Ask Their Oncology Team?
Patients do not need to become experts on the pharmaceutical supply chain.
But there are several practical questions worth asking if you are receiving chemotherapy or preparing to begin treatment.
1. Are any drugs in my treatment plan currently in shortage?
Your oncology center's pharmacy will usually have the most useful information about its own supply.
2. Do you expect the shortage to affect my treatment?
A shortage may exist without affecting your particular treatment schedule.
3. If my medication becomes unavailable, what alternatives are available?
Ask whether there is another evidence-based regimen and whether it is expected to work equally well for your particular cancer.
4. Would changing the treatment change my side effects?
Two drugs may fight the same cancer but have different toxicity profiles.
Ask how an alternative could affect nausea, neuropathy, kidney function, blood counts, diarrhea, mouth sores, fatigue, hydration, or other treatment-related problems.
5. Could the change delay my next treatment?
This is especially useful if insurance approval is required for a replacement regimen.
6. Should I contact my insurance company?
Usually your oncology practice handles prior authorization, but patients can sometimes help by understanding whether another approval is pending.
7. Who should I contact if I have questions about the shortage?
Many cancer centers have oncology pharmacists who can explain medication availability and treatment alternatives.
Can Patients Check Drug Shortages Themselves?
Yes, although your oncology team remains the best source for information about your own treatment.
The FDA maintains a public Drug Shortages Database showing current and resolved national shortages. The agency recommends that patients who find a medication listed in shortage speak with their health care provider or pharmacist about available treatment options.
Remember that supply can vary from one hospital to another.
A national shortage does not necessarily mean your cancer center has none of the drug.
Likewise, a local hospital may have supply constraints before they appear as a nationwide FDA shortage.
Are Generic Cancer Drugs Lower Quality?
No.
Generic drugs are not lower-quality versions of brand-name drugs simply because they cost less.
FDA-approved generic drugs contain the same active ingredient and must meet the same scientific standards for quality, strength, dosage form, and route of administration as their brand-name counterparts.
The problem with many generic cancer drugs is not that the medications themselves are inferior.
The problem is that the economics and manufacturing system around older generic medicines can make the supply vulnerable.
What Is Being Done About Cancer Drug Shortages?
FDA works with manufacturers to prevent and reduce shortages.
Possible actions include helping companies address manufacturing problems, working with other manufacturers to increase production, extending expiration dates when scientifically appropriate, and identifying additional sources of supply.
Those efforts do make a difference.
FDA reported that during 2025 it worked with manufacturers to prevent 330 potential drug shortages.
But the new NCCN survey shows that cancer centers continue to face substantial supply problems.
Pharmacy leaders surveyed by NCCN overwhelmingly supported stronger economic incentives for reliable, high-quality manufacturing of generic cancer medications. They also called for greater transparency about suppliers and earlier notification to FDA when manufacturers expect disruptions.
The Bigger Issue: Protecting Continuity of Cancer Treatment
When we talk about cancer treatment disruption, we usually think about side effects.
A patient may develop severe neuropathy, dehydration, mucositis, infection, low blood counts, or another complication that forces treatment to be delayed or modified.
Drug shortages reveal another kind of disruption.
A patient can be healthy enough for the next treatment and the oncologist can be ready to give it—but the medicine itself may be difficult to obtain.
That is why continuity of care depends on more than having effective cancer drugs.
It also requires:
Reliable pharmaceutical manufacturing
Strong hospital pharmacy systems
Evidence-based backup treatment plans
Efficient insurance processes
Good communication with patients
Supportive care that helps patients tolerate treatment once the medication is available
Modern cancer care is a chain.
A breakthrough therapy does little good if the patient cannot receive it when needed.
The Bottom Line
A new NCCN survey shows that cancer drug shortages remain widespread across leading U.S. cancer centers.
Every responding center reported at least one anticancer medication shortage. Ifosfamide was in short supply at 94% of centers, carboplatin at 71%, and cisplatin at 16%. More than one in five centers reported shortages involving at least five cancer medications.
Cancer centers are generally not simply allowing treatment to stop.
Doctors and pharmacists are conserving supplies, finding evidence-based alternatives, adjusting treatment when medically appropriate, and developing systems to keep patients on schedule.
But those solutions require time and coordination, and treatment changes can trigger additional insurance approvals.
For cancer patients, the most useful response is not panic.
It is information.
Ask whether your treatment is affected, what alternatives exist, whether a change could affect side effects or effectiveness, and whether your next treatment is expected to remain on schedule.
Frequently Asked Questions
Are chemotherapy drugs currently in shortage?
Yes. The September 2026 NCCN survey found shortages involving several anticancer medications at responding cancer centers, including ifosfamide, carboplatin, cisplatin, and BCG. Availability can vary by institution and can change over time.
Which chemotherapy drug had the largest shortage in the NCCN survey?
Ifosfamide was the most widely reported shortage, affecting 94% of responding centers. Carboplatin shortages were reported by 71%, while 16% reported cisplatin shortages.
Does a chemotherapy shortage mean my treatment will be canceled?
Not necessarily. Cancer centers may still have inventory or may use conservation strategies, schedule adjustments, or evidence-based alternative treatments. Talk with your oncology team about your specific regimen.
Can doctors substitute another chemotherapy drug?
Sometimes, but not always. Whether a substitute is appropriate depends on the cancer, stage, treatment goal, patient health, and available evidence. ASCO recommends evidence-based alternatives when adequate supplies of the preferred drug are unavailable.
Why are generic chemotherapy drugs often in shortage?
FDA says drug shortages can result from manufacturing quality problems, production delays, limited raw materials, increased demand, shipping problems, and discontinuations. Older generic drugs can also be economically unattractive for manufacturers, leaving fewer suppliers and less spare production capacity.
Can drug shortages delay cancer treatment?
They can. A shortage may require an oncology team to locate additional supply or develop an alternative treatment plan. The NCCN survey found that 90% of responding centers needed repeat prior authorization when treatment plans were modified because of shortages, creating the potential for additional delays.
Where can I check whether a cancer drug is in shortage?
The FDA maintains an online Drug Shortages Database. Patients should also ask their oncology team or oncology pharmacist because hospital inventory may differ from national availability.
Are generic chemotherapy drugs less effective than brand-name medications?
FDA-approved generic drugs must contain the same active ingredient and meet FDA standards for quality, strength, dosage form, and how the medicine is given. The shortage problem is primarily about supply and manufacturing capacity, not generics being less effective simply because they are generic.
References
U.S. Food and Drug Administration. Frequently Asked Questions About Drug Shortages.
U.S. Food and Drug Administration. Drug Shortages: Root Causes and Potential Solutions.
U.S. Food and Drug Administration. Supply Chain: FDA's Role.
American Society of Clinical Oncology. Drug Shortages: Clinical Guidance.
U.S. Food and Drug Administration. Generic Drugs: Questions & Answers.
For more information on how HuMOLYTE can support your gut health during chemotherapy, visit our product page or consult your health care provider.
This blog was reviewed by Dr. Sourabh Kharait.
This blog is for educational purposes only and is not intended as medical advice. Always consult with your healthcare provider before making any changes to your treatment plan, hydration strategies, or diet. The information provided here is based on general insights and may not apply to individual circumstances.
